Results 191 to 200 of about 21,454 (214)
Some of the next articles are maybe not open access.
Tolvaptan and Autosomal Dominant Polycystic Kidney Disease
New England Journal of Medicine, 2017Approximately half the patients with autosomal dominant polycystic kidney disease (ADPKD), a condition due to deficiency in polycystin 1 or 2, have end-stage kidney disease by 60 years of age.1,2 Once progression begins, the mean decline in the estimated glomerular filtration rate (GFR) is approximately 4 to 6 ml per minute per 1.73 m2 of body-surface ...
openaire +2 more sources
Choledocholithiasis in autosomal dominant polycystic kidney disease
Digestive and Liver Disease, 2021Sanjeev, Sachdeva +3 more
openaire +2 more sources
Epigenetics in autosomal dominant polycystic kidney disease
Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAutosomal dominant polycystic kidney disease (ADPKD) is the fourth leading cause of end-stage renal disease, contributing substantially to patient morbidity, mortality, and healthcare system strain. Emerging research highlights a pivotal role of epigenetics in ADPKD's pathophysiology, where mechanisms like DNA methylation, histone modifications, and ...
Zhipeng, Yan +13 more
openaire +2 more sources
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
New England Journal of Medicine, 2012Vicente E Torres +2 more
exaly
Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease
Kidney International, 2003Ann M Johnson
exaly
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
New England Journal of Medicine, 2010Andreas L Serra +2 more
exaly
Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
New England Journal of Medicine, 2014Kaleab Z Abebe +2 more
exaly
Autosomal Dominant Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease
2023Carrie L. Phillips +2 more
openaire +1 more source